Clinical Trial Details


Back to Clinical Trials Database

INTELLANCE 2: ABT 414 alone or ABT 414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group

Study documentation

Trial Status All trial activities ended
Dates Date of activation: 14-Jan-2015
Date Step1 close: 04-Jul-2016
Date Step2 close: 13-Jul-2016
Data management at EORTC Yes
Design Phase 2
Randomized open label
Targeted Sample size EORTC Groups: 240 - All Groups: 240
Study Staff
Type of cancer
Participating groups
Protocol summary
NCT number NCT02343406
EudraCT 2014-004438-24